痛风患者基于基线共病集群的5年共病发生与发作模式:初级保健队列研究
该前瞻性初级保健队列研究纳入英国西米德兰兹20家全科诊所的成年痛风患者,随访5年,基于基线共病状态划分的4个集群,分析新发共病和痛风发作与集群归属的关联。结果显示冠状动脉疾病发生率最高(39.2%),集群归属与新发冠状动脉疾病、高脂血症、心力衰竭和高血压显著相关,但集群归属与痛风发作无关联。
要点
- 每个集群中近三分之一参与者在各时间点报告两次及以上痛风发作。
- 寡/多关节发作史(OR=2.16,95%CI:1.73,2.70)和肥胖(OR=1.66,95%CI:1.21,2.25)与发作增加相关。
- 当前使用别嘌醇与发作风险降低相关(OR=0.42,95%CI:0.34-0.53)。
核心结论
- 每个集群中大量患者出现新发共病,且新发共病因集群归属而异。
- 患者随时间经历多次发作,但发作模式在集群间无差异。
- 临床医生应警惕痛风患者新发共病的发生。
研究设计与样本
- 前瞻性初级保健队列研究,纳入英国西米德兰兹20家全科诊所的≥18岁痛风成人,随访5年。
- 基线按共病状态预先定义4个集群,采用年龄和性别调整的Poisson回归分析新发共病,混合效应有序logistic回归分析痛风发作。
主要发现
- 新发共病发生率最高为冠状动脉疾病(39.2%),其次为高血压(36.7%)、慢性肾脏病≥3期(18.1%)、肥胖(16.0%)、高脂血症(11.7%)、糖尿病(8.8%)和癌症(8.4%)。
- 集群归属与新发冠状动脉疾病、高脂血症、心力衰竭和高血压存在统计学显著关联。
- 每个集群中近三分之一参与者在各时间点报告两次及以上痛风发作。
- 寡/多关节发作史(OR=2.16,95%CI:1.73,2.70)和肥胖(OR=1.66,95%CI:1.21,2.25)与发作增加相关,当前使用别嘌醇与发作风险降低相关(OR=0.42,95%CI:0.34-0.53)。
- 集群归属与痛风发作无关联。
临床怎么用
- 对痛风患者应警惕新发共病,尤其冠状动脉疾病、高血压、慢性肾脏病、肥胖、高脂血症、糖尿病和癌症。
- 管理痛风发作时需关注寡/多关节发作史和肥胖,并优化别嘌醇使用以降低发作风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the onset of comorbidities and pattern of flares over 5 years according to baseline comorbidity clusters in people with gout. METHODS: In a prospective primary care-based cohort study, adults aged ≥18 years with gout were identified from primary care medical records in 20 general practices across the West Midlands, UK and followed up over 5 years. Four clusters of participants have been defined previously according to baseline comorbidity status. The associations of (i) incident comorbidities and (ii) gout flares with baseline cluster membership were estimated using age and sex-adjusted Poisson regression and mixed effects ordinal logistic regression, respectively. RESULTS: The comorbidity with the highest incidence was coronary artery disease (39.2%), followed by hypertension (36.7%), chronic kidney disease stage ≥3 (18.1%), obesity (16.0%), hyperlipidaemia (11.7%), diabetes (8.8%) and cancer (8.4%). There were statistically significant associations observed between cluster membership and incidence of coronary artery disease, hyperlipidaemia, heart failure and hypertension. In each cluster, nearly one-third of participants reported two or more gout flares at each time-point. History of oligo/polyarticular flares (odds ratio [OR]= 2.16, 95% confidence interval [CI]: 1.73, 2.70) and obesity (1.66, 95% CI: 1.21, 2.25) were associated with increasing flares whereas current use of allopurinol was associated with lower risk (0.42, 95% CI: 0.34-0.53). Cluster membership was not associated with flares. CONCLUSION: Substantial numbers of people in each cluster developed new comorbidities that varies by cluster membership. People also experienced multiple flares over time, but these did not differ between clusters. Clinicians should be vigilant for the development of new comorbidities in people with gout.
引用
- Bajpai R, Muller S, Mallen C, et al. Onset of comorbidities and flare patterns within pre-existing morbidity clusters in people with gout: 5-year primary care cohort study. Rheumatology (Oxford). 2021. PMID: 33744931. doi:10.1093/rheumatology/keab283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。